Search Results 201-210 of 7952 for TNF

1. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   ... tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab. Exclusion Criteria: Presence of Crohn's disease, indeterminate colitis, ischemic colitis ...

2. A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis - Mayo Clinic

   ... TNF therapy within 12 weeks prior to Screening (Visit 1); Anti-CD52 (alemtuzumab) within 6 months prior to Screening (Visit 1). Liver Function Tests ...

3. Phase 3 Program to Evaluate MK-7240 for Moderate to Severe Ulcerative Colitis - Mayo Clinic

   An anti-TNF agent;; An anti-integrin (eg, vedolizumab);; A JAK inhibitor (eg, tofacitinib, upadacitinib, or filgotinib);; An anti-IL-23 or anti-IL-12/23 for UC ...

4. A Study to Evaluate the Accuracy of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   Participation eligibility · biologic therapy targeted at tumor necrosis factor alpha (eg, infliximab, adalimumab, golimumab, etanercept, certolizumab); ...

5. A Phase 1/2 Study to Evaluate MEDI4736 - Mayo Clinic

   Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural ...

6. A Study of the Safety and Effectiveness of RoActemra/Actemra (Tocilizumab) for Patients with Giant Cell Arteritis - Mayo Clinic

   Tumor necrosis factor inhibitors within 2-8 weeks of baseline; Anakinra within 1 week of baseline; Corticosteroids for conditions other than GCA; IV ...

7. Publications - Regan N. Theiler, M.D., Ph.D. - Mayo Clinic

   Effect of Anti-TNF Biologic Exposure During Pregnancy on Villitis of Unknown Etiology Diagnoses in Patients with Autoimmune Disease. Reprod Sci. 2024 Apr ...

8. Publications - Clement J. Michet, Jr., M.D. - Mayo Clinic

   ... Tumor Necrosis Factor ... 2012 Mar; 18: (2)92-5. View PubMed; Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors ...

9. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   ... tumor necrosis factor agents) with the exception of corticosteroid treatment < 20 mg/day prednisone or equivalent within 7 days prior to first dose of ICP-022:.

10. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) is allowed, provided the following is met: minimum of 2 weeks prior to Cycle 1, Day 1. Patients who have received ...